FDA Pushes High-Tech Tweaks to Speed Up Meds Production
Published Date: 12/1/2025
Notice
Summary
The FDA is rolling out a new plan to speed up and support cool, high-tech ways to make medicines from 2023 to 2027. This means drug makers will get help using smarter manufacturing tools, making medicine safer and faster to produce. If you’re in the drug business, get ready for fresh rules and chances to share your thoughts starting early 2026!
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Strategy to Reduce Drug Shortages
The FDA's Strategy Document (covering fiscal years 2023-2027) says innovative manufacturing technologies can increase product development speed, bolster supply chains, improve drug quality, and prevent drug shortages. The Agency announced the strategy in the Federal Register on January 30, 2026.
New AMTDP Implementation Plans
FDA will implement the Advanced Manufacturing Technologies Designation Program (AMTDP) and says it will incorporate feedback on eligibility criteria as part of its fiscal years 2023-2027 activities. The Strategy Document was announced in the Federal Register on January 30, 2026.
Expanded Support via ETP and CATT
FDA will continue to enhance the Center for Drug Evaluation and Research Emerging Technology Program (ETP) and the Center for Biologics Evaluation and Research Advanced Technologies Team (CATT) to support use of innovative manufacturing technologies during fiscal years 2023-2027. The Strategy Document was announced on January 30, 2026.
International Harmonization Efforts
FDA says it will continue to identify opportunities for international harmonization of regulatory expectations to support wider adoption of advanced manufacturing technologies as part of its 2023-2027 strategy. The Strategy Document announcement date is January 30, 2026.
FDA Staff Training on Advanced Manufacturing
The Strategy Document says FDA will support training in advanced manufacturing for FDA regulatory staff as part of activities for fiscal years 2023-2027. The document was announced in the Federal Register on January 30, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-21691, Slag Pots From China; Determinations
The U.S. found that slag pots imported from China are being sold at unfairly low prices and are backed by Chinese government subsidies, hurting American companies like WHEMCO-Steel Castings. Because of this, the U.S. will take action to protect its industry, which could mean new rules or tariffs soon. This decision affects importers and manufacturers and signals changes that might impact prices and trade starting in early 2026.
Next: 2025-21693, Initiation of Five-Year (Sunset) Reviews
The U.S. Department of Commerce is kicking off its automatic five-year checkups called Sunset Reviews on certain trade duties to see if they should stay or go. This affects businesses involved in imports and exports with ongoing antidumping and countervailing duty orders. These reviews started November 3, 2025, and could impact trade costs and rules soon.